RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Bengbu Medical University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Bengbu Medical University蚌埠医学院第一附属医院BengbuHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT03177902, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 85 years; sex: women only

    Registered eligibility fields

  2. Female patients with histologically or cytologically proven primary breast cancer;

    Inclusion criterion 1

  3. ECOG Performance Status: 0-2;

    Inclusion criterion 3

  4. Pregnancy or lactation;

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT03177902, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Female patients with histologically or cytologically proven primary breast cancer;
  • Age >18 years;
  • ECOG Performance Status: 0-2;
  • Life Expectancy: 3 months or more;
  • No previous anti-cancer therapy;
  • Be willing to undergo at least four cycles of anthracycline or taxane-based chemotherapy;
  • Adequate hematological, liver, and kidney functions.

Exclusion Criteria:

  • Pregnancy or lactation;
  • History of other malignancy or secondary breast cancer;
  • History of thyroid disease;
  • History of drug addiction or abuse;
  • History of immunodeficiency disease;
  • Treatment with drugs capable of influencing thyroid gland functions within 3 months prior to study entry;
  • Nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases;
  • Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials;
  • Inability to understand and agree to informed consent.

Quoted from ClinicalTrials.gov, NCT03177902, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT03177902, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT03177902